Paragon Care Limited · ASX:PGC
Paragon Care — Investor Presentation (August 2024)
17 slides from Paragon Care's investor presentation, Aug 30, 2024
Slide 1: Annual Financial Results Investor Presentation, Year Ended 30 June 2024
Annual Financial Investor Presentation Results Year Ended 30 June 2024 30th August 2024
Slide 2: Disclaimer
Disclaimer This document has been prepared by Paragon Care Limited ACN 064 551 426 (ASX: PGC) (ParagonCare or the Company) (Presentation). The material in this Presentation contains general background information about ParagonCare and its current activities as at the date of this Presentation. The i
Slide 3: Overview of ParagonCare
Overview of ParagonCare
Slide 4: ParagonCare completed the merger with CH2 in June 2024
ParagonCare completed the merger with CH2 in June 2024 - the combined entity offers a compelling value proposition to customers and supply partners An expanded product range for cross-selling and bundling A focus on operational efficiency, covering pharmaceutical, nutritional, medical quality servic
Slide 5: ParagonCare is a leading healthcare wholesaler, distributor & manufacturer
ParagonCare is a leading healthcare wholesaler, distributor & manufacturer* FY24 Proforma FY24 Proforma FY24 Proforma Revenue** EBITDA** Net Profit After Tax** $3.33 billion $90.8 million $28.4 million FY24 Statutory FY24 Statutory FY24 Statutory Revenue*** EBITDA*** Net Profit After Tax*** $2.97 bi
Slide 6: Restructured into a new Business and Shared Services model
Restructured into a new Business and Shared Services model Business Development - Category Management - Customer and Supplier Relationships CAPITAL,SERVICE AND COMPLEMENTARY PHARMACY DIAGNOSTICS SURGICAL SPECIALITIES CONTRACT LOGISTICS MEDICAL CONSUMABLES MEDICINES Revenue: $2,491m Revenue: $695m Re
Slide 7: Focus on operational efficiency, quality service and competitive pricing
Focus on operational efficiency, quality service and competitive pricing The merged entity will benefit from cost synergies through network optimisation and the implementation of a shared services model Specific initiatives include: The consolidation of warehouse locations in Australia and the optim
Slide 8: Consolidating to 8 warehouse locations in Australia and expanding New Zealand and Asia
Consolidating to 8 warehouse locations in Australia and expanding New Zealand and Asia. Broad combined geographical reach Australia - New Zealand - Philippines - Thailand - Korea - Japan - Vietnam Planned expansion to Singapore, Malaysia and Indonesia
Slide 9: New Mount Waverley facility to support sovereign manufacturing capability
New Mount Waverley facility to support sovereign manufacturing capability ParagonCare Diagnostics has a unique manufacturing and distribution capability through Immulab ParagonCare | Immulab manufactures immunohaematology In-Vitro Diagnostics, which are primarily used in Blood Banks. ParagonCare | I
Slide 10: Executing on the integration plan
Executing on the integration plan New Shared Designs for SMS and Oborne will be ISO14001 REM Systems Balance of Engagement Organisational service Vision LabGear on fully integrated accreditation targeted for Australia, Asia with all key structure in team merged: Australia now track for by end of by
Slide 11: Experienced Board with significant expertise in the healthcare sector
Experienced Board with significant expertise in the healthcare sector David Collins Carmen Riley Peter Lacaze Alan McCarthy John Walstab Chief Executive Officer Executive Director/Chief Chairman Non-Executive Director Executive Director and Executive Operating Officer General Manager Paragon Care As
Slide 12: FY24 Financial Results Key Highlights
FY24 Financial Results Key Highlights
Slide 13: FY24 P&L: Proforma & Statutory
FY24 P&L: Proforma & Statutory $m FY24 FY23 Var $ Var % Commentary Strong revenue growth on a proforma basis due to: Underlying EBITDA • CH2 up 31.4% - CHS acquisition, market share gains, and market Revenue 3,336.3 2,494.9 841.4 33.72% growth. • Oborne up 21.7% - strong organic growth in the core E
Slide 14: FY24 Balance Sheet: Statutory
FY24 Balance Sheet: Statutory $m FY24 FY23 Var $ Var % Receivables 350.6 209.9 115.3 54.9% Commentary Inventory 307.7 215.8 91.9 42.6% Balance Sheet materially changed due to the CHS, Oborne acquisitions, and ParagonCare merger. Trade payables (553.1) (374.1) (179) 47.8% Working capital increase due
Slide 15: FY24 Cash Flow & Net Debt: Statutory
FY24 Cash Flow & Net Debt: Statutory $m FY24 FY23 Var $ Var % Cash flows from operating activities 74.4 37.1 37.3 101% Net interest paid 14.6 10.9 3.7 33.9% Tax (paid) 5.9 3.9 2 51.3% Commentary Free cash driven by improved working capital management Net cash from operating activity 53.9 22.4 31.5 1
Slide 16: FY25 Outlook
FY25 Outlook Continued execution on the integration plan for the merged entity. Increase cross-sell of expanded product range and bundled offerings. Focus on operational efficiency and cost rationalisation. Inaugural ParagonCare Annual Conference in October 2024, with over 250 team members to reset
Slide 17: Thank you.
Thank you. ParagenCare Enabling Healthcare